GOLDEN ARTHUR F 4

What Happened Arthur F. Golden, a director of Turn Therapeutics (TTRX), received a derivative award on 2026-06-04 covering 89,584 shares. The filing reports an acquisition price of $0.00 and classifies the transaction as an award/grant (derivative instrument) rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (appears timely — within the 2 business‑day reporting window).
• Transaction type/code: Award/Grant (derivative) — reported as A.
• Shares/units granted: 89,584 (reported acquisition value $0.00).
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: The option will vest in twelve (12) equal monthly installments on the last day of each month, commencing June 30, 2026, subject to continued service and the Issuer’s 2025 Omnibus Incentive Plan.
• No indication in this filing of an immediate sale (cashless exercise) or tax withholding action.

Context This was a compensation-related option grant to a director, not an open‑market buy or sell. For retail investors, award grants signal executive/board compensation but do not necessarily indicate a near-term buying or selling conviction. The listed vesting schedule means the award converts into exercisable rights over the next year, contingent on continued service and plan terms.